2024-514634-20-00CompletedPhase 1
Characterization of Immune Response in Participants from a Posdinemab Study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 May 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 30 Aug 2024
- Start date
- 25 Feb 2025
- Lead sponsor
- Janssen Cilag International
- Diseases
- Alzheimer disease
- EU CT number
- 2024-514634-20-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- 4 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fundacion Para La Investigacion Biomedica Del Hospital Clinico San Carlos | Madrid | Spain | Completed |
| Pellegrin Hospital | Bordeaux | France | Completed |
| Centre Hospitalier Universitaire De Lille | Lille Cedex | France | Completed |
| Brain Research Center Den Bosch B.V. | 's-Hertogenbosch | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.